ClinicalTrials.gg
CompletedNCT02525133MATRIX-2Updated Jan 8, 2021Results posted

Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty

A Phase 3 interventional study of XaraColl and Placebo in Pain, Postoperative, sponsored by Innocoll. Completed at 24 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-08.

Sponsored by Innocoll · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
319
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
10th of 364
319 · median 70
Started
2015
with 24 others
Phase 3
42 of 364
2 open now
Registered
76th of 364
by date
Lead sponsor
6 of 364
Innocoll

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 10th largest by enrollment, is one of 25 that started in 2015, is one of 42 in phase 3, and was the 76th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled efficacy and safety study of postoperative pain in adults who are scheduled for unilateral inguinal hernioplasty via open laparotomy (tension-free technique).

Patients will assess their postoperative pain intensity (PI) using an 11-point numerical rating scale (NRS) from 0 hour through 72 hours postoperatively.

The expected maximum study duration for each patient will be up to 60 days, including a maximum 30-day screening period, the day of surgery and implantation, and a 30-day post implantation period including treatment and follow-up.

Read the detailed description

This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adults who are scheduled for unilateral inguinal hernioplasty via open laparotomy (tension-free technique). Patients will receive either 3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose; or 3 placebo-sponges.

Three test article sponges will be implanted according to the patient's blinded treatment assignment. Following surgery, patients will be transferred to a postanesthesia care unit (PACU) and/or other postoperative recovery area for observation where they may receive parenteral morphine as needed (rescue medication for breakthrough pain) and on request for pain control. Once patients can tolerate oral medication, they will commence a standardized oral analgesic regimen with additional PRN medication to manage breakthrough pain only when it occurs.

Patients will assess their postoperative pain intensity (PI) using an 11-point numerical rating scale (NRS) from 0 hour through 72 hours postoperatively.

Patients will be observed postoperatively for a minimum of 3 hours and may be discharged at any time following completion of their 3-hour vital sign and PI assessments. Patients will be contacted at approximately 6, 24 and 48 hours after implantation to ensure protocol compliance and to perform safety assessments (including AEs and concomitant medications). At 72 hours, patients will return to the clinic to perform their final PI assessment, complete a categorical assessment of their overall pain control, and for follow-up safety assessments. They will also be asked to record the incidence of any ongoing or subsequent AEs (and any associated treatment) through Day 7. Additional follow-up assessments for safety will be performed at postoperative Day 7 (telephone call) and Days 15 and 30 (clinic visits).

03

Conditions studied

  • Pain, Postoperative

Browse trials for

Keywords

  • post operative pain
  • hernioplasty
  • bupivacaine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a planned (non-emergent) unilateral inguinal hernioplasty (open laparotomy, tension-free technique) to be performed according to standard surgical technique under general anesthesia. Repair of multiple hernias through a single incision is permitted provided only a single mesh will be used.
  • If female, is nonpregnant and nonlactating.
  • If female, is either not of (defined as for ≥ 1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy or hysterectomy]) or practicing 1 of the protocol specified medically-acceptable methods of and agrees to continue with the regimen throughout the duration of the study:
  • Has the ability and willingness to comply with the study procedures and use of the eDiary.
  • Is willing to use only permitted medications throughout the study.
  • Is willing to use opioid analgesia.
  • Must be able to fluently speak and understand either English or Spanish and be able to provide meaningful written for the study.

Exclusion criteria

Exclusion Criteria:

  • Has a known to amide local anesthetics, morphine, acetaminophen or bovine products.
  • Is scheduled for bilateral inguinal hernioplasty or other significant concurrent surgical procedures per investigator discretion.
  • Has undergone major surgery within 3 months of the scheduled hernioplasty or plans to undergo another laparotomy procedure within 30 days postoperatively.
  • Has used any analgesic other than acetaminophen within 24 hours of surgery. Acetaminophen may be used on the day of surgery but is subject to preoperative restrictions for oral intake.
  • Has used aspirin or aspirin-containing products within 7 days of surgery. Aspirin at a dose of ≤ 325 mg is allowed for cardiovascular prophylaxis if the patient has been on a stable dose regimen for ≥ 30 days before Screening.
  • Has used systemic , anticonvulsants, antiepileptics, antidepressants for the management of chronic pain, or monoamine oxidase inhibitors on a regular basis within 10 days of surgery.
  • Has used any opioid analgesic for an extended daily basis (30 - 60 mg oral morphine equivalent per day for 3 or more days a week) within 4 weeks before surgery. Patients who, in the investigator's opinion, may be developing opioid tolerance are also excluded.
  • Has any chronic painful condition (eg, fibromyalgia) or routinely uses pain medication other than acetaminophen (including nonsteroidal anti-inflammatory drugs [NSAIDs]) that, in the opinion of the investigator, may confound the assessment of pain associated with the hernioplasty.
  • Has a physical or mental condition that, in the opinion of the investigator, may confound the assessment of postoperative pain after hernioplasty.
  • Shows evidence of tolerance or physical dependency on opioid analgesics or sedative-hypnotic medications.
  • Has a urine drug screen that tests positive for drugs of abuse or misuse, including cannabinoids.
  • Has liver function test results greater than 3x the or a history of cirrhosis.
  • Has any unstable cardiac disease (eg, uncontrolled hypertension, clinically significant arrhythmia at baseline, or an implantable cardioverter-defibrillator [ICD])
  • Has any clinically significant unstable neurological, immunological, renal, or hematological disease (eg, uncontrolled diabetes or significantly abnormal laboratory findings), or any other condition that, in the opinion of the investigator, could compromise the patient's welfare, ability to communicate with the study staff or otherwise contraindicate study participation.
  • Has an open workman's compensation claim.
  • Has participated in a clinical trial ( or marketed product) within 30 days of surgery.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
319 participants (actual)

Study arms

  • Experimental
    XaraColl

    3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose

    Drug: XaraColl

  • Placebo comparator
    Placebo

    3 placebo implants

    Other: Placebo

Interventions

  • Surgical implantation of 3 bupivacaine collagen implants

    Also known as: Bupivacaine collagen implant

  • OtherPlacebo

    Plain collagen implant (vehicle)

    Also known as: Collagen implant

06

What researchers measure

Primary outcomes

  1. SPI24

    The primary efficacy variable (time-weighted sum of pain intensity from Time 0 through 24 hours \[SPI24\]) was compared once at a 2-sided 0.05 level. Therefore, no multiplicity adjustment was necessary for the primary efficacy analysis. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated "no pain" and 10 indicated "worst pain possible". Minimum value would be "0" and Maximum value would be 240. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI24 = ∑\[PI x (time t - time t-1)\], where "t" represents a given time point,"t-1" represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.

    Time frame: 0 to 24 hours

Secondary outcomes

  1. TOpA24

    Total use of opioid analgesia (TOpA) from Time 0 through 24 hours (TOpA24) This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had to use within a 24-hour period (typically called "rescue" to help manage pain. Zero (0) is the "lowest" score. The lower the number of tablets the better outcome.

    Time frame: Time 0 through 24 hours

  2. TOpA48

    Total use of opioid analgesia (TOpA) from Time 0 through 48 hours (TOpA48) This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had use within a 48-hour period (typically called "rescue" to help manage pain. Zero (0) is the "lowest" score. The lower the number of tablets the better outcome.

    Time frame: Time 0 through 48 hours

  3. TOpA72

    Total use of opioid analgesia (TOpA) from Time 0 through 72 hours (TOpA72) This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had use within a 72-hour period (typically called "rescue" to help manage pain. Zero (0) is the "lowest" score. The lower the number of tablets the better outcome.

    Time frame: Time 0 through 72 hours

  4. SPI48

    Time-weighted sum of pain intensity from Time 0 through 48 hours (SPI48). Lower score has a better outcome. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated "no pain" and 10 indicated "worst pain possible". Minimum value would be "0" and Maximum value would be 480. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI48 = ∑\[PI x (time t - time t-1)\], where "t" represents a given time point,"t-1" represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.

    Time frame: 0 to 48 hours

  5. SPI72

    Time-weighted sum of pain intensity from Time 0 through 72 hours (SPI72) A lower score is a better outcome. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated "no pain" and 10 indicated "worst pain possible" Minimum value would be "0" and Maximum value would be 720. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI72 = ∑\[PI x (time t - time t-1)\], where "t" represents a given time point,"t-1" represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.

    Time frame: 0 to 72 hours

07

Results

Posted Jan 8, 2021

Participant flow

Participant flow — Overall Study
MilestoneXaraCollPlacebo
Started213106
Randomized but not treated40
Completed203103
Not completed103
Withdrew: Adverse event01
Withdrew: Death01
Withdrew: Did not meet randomization criteria10
Withdrew: Lost to follow-up51
Withdrew: Randomized not enrolled30
Withdrew: Withdrawal by subject10

Outcome measures

PrimarySPI24

The primary efficacy variable (time-weighted sum of pain intensity from Time 0 through 24 hours \[SPI24\]) was compared once at a 2-sided 0.05 level. Therefore, no multiplicity adjustment was necessary for the primary efficacy analysis. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated "no pain" and 10 indicated "worst pain possible". Minimum value would be "0" and Maximum value would be 240. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI24 = ∑\[PI x (time t - time t-1)\], where "t" represents a given time point,"t-1" represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.

Time frame:
0 to 24 hours
Reported as:
Mean · units on a scale
SPI24
units on a scaleXaraCollPlacebo
SPI2488.3 ± 47.01116.2 ± 44.04
SecondaryTOpA24

Total use of opioid analgesia (TOpA) from Time 0 through 24 hours (TOpA24) This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had to use within a 24-hour period (typically called "rescue" to help manage pain. Zero (0) is the "lowest" score. The lower the number of tablets the better outcome.

Time frame:
Time 0 through 24 hours
Reported as:
Median · morphine equivalents
TOpA24
morphine equivalentsXaraCollPlacebo
TOpA245.0 (0.0 to 70.0)14 (0.0 to 53.0)
SecondaryTOpA48

Total use of opioid analgesia (TOpA) from Time 0 through 48 hours (TOpA48) This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had use within a 48-hour period (typically called "rescue" to help manage pain. Zero (0) is the "lowest" score. The lower the number of tablets the better outcome.

Time frame:
Time 0 through 48 hours
Reported as:
Median · morphine equivalent
TOpA48
morphine equivalentXaraCollPlacebo
TOpA485 (0.0 to 70.0)14 (0.0 to 53.0)
SecondaryTOpA72

Total use of opioid analgesia (TOpA) from Time 0 through 72 hours (TOpA72) This is a basic measurement of counting in total the number of morphine tablets (15 mg) patients had use within a 72-hour period (typically called "rescue" to help manage pain. Zero (0) is the "lowest" score. The lower the number of tablets the better outcome.

Time frame:
Time 0 through 72 hours
Reported as:
Median · morphine tablets
TOpA72
morphine tabletsXaraCollPlacebo
TOpA7210 (0.0 to 90.0)20 (0.0 to 73.0)
SecondarySPI48

Time-weighted sum of pain intensity from Time 0 through 48 hours (SPI48). Lower score has a better outcome. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated "no pain" and 10 indicated "worst pain possible". Minimum value would be "0" and Maximum value would be 480. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI48 = ∑\[PI x (time t - time t-1)\], where "t" represents a given time point,"t-1" represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.

Time frame:
0 to 48 hours
Reported as:
Median · units on a scale
SPI48
units on a scaleXaraCollPlacebo
SPI48188.1 (0.0 to 435.8)214.9 (0.0 to 429.3)
SecondarySPI72

Time-weighted sum of pain intensity from Time 0 through 72 hours (SPI72) A lower score is a better outcome. Pain Intensity was assessed by the subject using the 11-point NRS, where 0 indicated "no pain" and 10 indicated "worst pain possible" Minimum value would be "0" and Maximum value would be 720. Time-weighted SPI is calculated as the sum of the pain intensities between successive time points (i.e., if SPI72 = ∑\[PI x (time t - time t-1)\], where "t" represents a given time point,"t-1" represents the previous time point, and time is expressed in hours). This represents the AUC (Area Under the Curve) of the pain intensities when calculated with the trapezoidal rule.

Time frame:
0 to 72 hours
Reported as:
Median · units on a scale
SPI72
units on a scaleXaraCollPlacebo
SPI72264.5 (0.0 to 651.7)299.7 (62.8 to 645.3)

Adverse events

Collected over 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
XaraColl0/208 (0%)3/208 (1.4%)118/208 (56.7%)
Placebo1/107 (0.9%)3/107 (2.8%)76/107 (71%)
Most frequent serious events
Most frequent serious events
EventXaraCollPlacebo
Acute myocardial infarctionCardiac disorders1/2081/107
Abdominal painGastrointestinal disorders0/2081/107
Groin painMusculoskeletal and connective tissue disorders0/2081/107
Atrial fibrillationCardiac disorders1/2080/107
AppendicitisInfections and infestations1/2080/107
Most frequent other events
Most frequent other events
EventXaraCollPlacebo
DizzinessNervous system disorders34/20822/107
ConstipationGastrointestinal disorders18/20819/107
NauseaGastrointestinal disorders16/20819/107
SomnolenceNervous system disorders33/20819/107
Incision site painInjury, poisoning and procedural complications19/20813/107
Incision site swellingInjury, poisoning and procedural complications18/20811/107
DysgeusiaNervous system disorders17/20810/107
RestlessnessPsychiatric disorders16/20810/107
AnxietyPsychiatric disorders6/2088/107
Incision site complicationInjury, poisoning and procedural complications13/2086/107

Baseline characteristics

The modified intent-to-treat (mITT) population consisted of all randomized subjects who received any dose of INL-001 or placebo and who had at least 1 NRS PI score prior to hospital discharge

Age, Continuous
Age, Continuous(years)XaraCollPlaceboTotal
Mean50.7 ± 13.6948.5 ± 13.8450.0 ± 13.79
Sex: Female, Male
Sex: Female, Male(Participants)XaraCollPlaceboTotal
Female538
Male202102304
08

Study locations

24 sites
  • Anniston, Alabama 36207, United States
  • Birmingham, Alabama 35216, United States
  • Anaheim, California 92801, United States
  • Laguna Hills, California 92653, United States
  • Pasadena, California 91105, United States
  • Placentia, California 92870, United States
  • Aurora, Colorado 80045, United States
  • Miami, Florida 33134, United States
  • Miami, Florida 33155, United States
  • Pembroke Pines, Florida 33028, United States
  • Pensacola, Florida 32503, United States
  • Columbus, Georgia 31904, United States
  • Chicago, Illinois 60645, United States
  • Las Vegas, Nevada 89104, United States
  • Durham, North Carolina 27710, United States
  • Cleveland, Ohio 44106, United States
  • Columbus, Ohio 43210, United States
  • Oklahoma City, Oklahoma 73104, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Houston, Texas 77004, United States
  • Houston, Texas 77024, United States
  • Salt Lake City, Utah 84124, United States
  • Newport News, Virginia 23606, United States
  • Madison, Wisconsin 53792, United States
09

References and documents

Publications

  • Velanovich V, Rider P, Deck K, Minkowitz HS, Leiman D, Jones N, Niebler G. Safety and Efficacy of Bupivacaine HCl Collagen-Matrix Implant (INL-001) in Open Inguinal Hernia Repair: Results from Two Randomized Controlled Trials. Adv Ther. 2019 Jan;36(1):200-216. doi: 10.1007/s12325-018-0836-4. Epub 2018 Nov 22. PubMed 30467808 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2021, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2015
First posted
Aug 17, 2015
Start
Sep 5, 2015
Primary completionActual
Apr 22, 2016
CompletionActual
Apr 22, 2016
Results first posted
Jan 8, 2021
Last update
Jan 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02525133
Lead sponsor
Innocoll
Responsible party
Sponsor
First posted
Aug 17, 2015
Start date
Sep 5, 2015
Primary completion
Apr 22, 2016
Completion
Apr 22, 2016
Results posted
Jan 8, 2021
Last update
Jan 8, 2021

Study contacts

Gwendolyn Niebler, D.O.
study director · Innocoll

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion